Camrelizumab-Associated Psoriasis

Am J Ther. 2023 Sep-Oct;30(5):e461-e463. doi: 10.1097/MJT.0000000000001591. Epub 2022 Dec 23.

Authors

Hai-Zhen Hui^{1

2}, Ying-Jun Wang^{1

2}, Jia-Rong Cheng^{1

2}, Han Mao^{1

2}, Xue Jiang¹, Hong-Xing Guo³, Qing-Chun Diao¹, Bing-Jun Shi¹

Affiliations

¹ Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine (Chongqing Clinical Research Center for Dermatology; Chongqing Key Laboratory of Integrative Dermatology Research), District Yuzhong, Chongqing, PR China.
² Guizhou University of Traditional Chinese Medicine, Guiyang, PR China.
³ Kweichow Moutai Hospital, Renhuai, PR China.

PMID: 37713694
DOI: 10.1097/MJT.0000000000001591

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Humans
Psoriasis* / chemically induced

Substances

camrelizumab
Antibodies, Monoclonal, Humanized